Omniab, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
OABI
Omniab, INCOmniAb, Inc. reported a 29% decrease in total revenue and an increased net loss for fiscal year 2025, despite growth in active partnerships and the launch of new antibody discovery technologies.
NASDAQ
OABI
Omniab, INCOmniAb's 2024 10-K filing reveals a decrease in revenue but growth in active partnerships and programs, alongside ongoing investments in its technology platform.
NASDAQ
OABI
Omniab, INC10-K: OmniAb, Inc. Reports Full Year 2023 Results, Highlights Platform Growth and Strategic Investments
OmniAb, Inc. reported its full year 2023 results, showcasing growth in partnerships and programs, while also detailing strategic investments in technology and infrastructure.